Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.

Damanhour University180 enrolled

Overview

The association of novel inflammatory biomarkers with cardiovascular diseases is still obscure. The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission. Methods: We enrolled a total of 120 patients with HF, asymptomatic CAD and 60 healthy controls (HC) without cardiovascular diseases.

* The present study aimed to investigate the relationship of various inflammatory biomarkers with the existence as well as the extent of heart failure (HF) and coronary artery disease (CAD), suggesting a link between inflammation and cardiovascular diseases and all-cause 30- and -90 day of hospital readmission in patients on empagliflozin 10 mg once daily for 6 months before the beginning of the study. * We enrolled a total of 60 patients with HF, 60 asymptomatic CAD patients and 60 healthy controls (HC) without cardiovascular diseases. Group I: 60 Healthy Subjects. Group II: 60 Patients with Stable Angina (asymptomatic CAD). Group III: 60 Patients with Heart Failure. * Clinical parameters, glycemic and lipid profile, vaspin, visfatin, high-sensitivity C-reactive protein, sortilin, homocysteine, troponin I, fetuin A and lipoprotein A levels were assayed. * Patients will be followed up to assess all-cause 30- and -90 day of hospital readmission.

Study Type

OBSERVATIONAL

Enrollment

180

Conditions

Stable Angina Heart Failure

Interventions

Group I HealthyOTHER

Healthy Subjects

CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the studyDRUG

Group II: Stable Angina Patients

HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the studyDRUG

Group III: Heart Failure Patients

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Either sex, aged 18 years or older. * new-onset AHF or acute decompensation of chronic HF, * CAD (including previous myocardial infarction, previous percutaneous or surgical coronary revascularization, or angiographic evidence that one or more major coronary arteries had narrowed by 50% or more). * On empagliflozin 10 mg once daily for 6 months before the beginning of the study. Exclusion Criteria: * severe liver/ * kidney dysfunction; * severe systemic disease (such as the diseases of respiratory system/ digestive system/ nervous system etc.); * malignant tumor; * acute/ chronic infectious diseases; * autoimmune disease or connective tissue disease; * major trauma or surgical operation over the past three months.

Locations (1)

Tanta University Hospital

Tanta, El-Gharbia, Egypt

Outcomes

Primary Outcomes

All Cause 30 day hosptial admission

Number of patients admited to hospital during 1 month.

Time frame: 1 month

All Cause 90 day hosptial admission

Number of patients admited to hospital during 3 month.

Time frame: 3 months

vaspin (ng/ml)

vaspin blood concentration

Time frame: 1 month

visfatin (ng/ml)

visfatin blood concentration

Time frame: 1 month

Sortillin (pg/ml)

Sortillin blood concentration

Time frame: 1 month

Homocystien(umol/L)

Homocystien blood concentration

Time frame: 1 Month

Troponin.I (ng/ml)

Troponin.I blood concentration

Time frame: 1 Month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.